• 1
    Herr HW, Laudone VP, Whitmore WF. An overview of intravesical therapy for superficial bladder tumors. J Urol. 1987; 138: 13631368.
  • 2
    Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991; 325: 12051209.
  • 3
    Witjes JA, Meijden AP, Sylvester LC, Debruyne FM, van Aubel A, Withes WP. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology. 1998; 52: 403410
  • 4
    Kurth KH, Bouffioux C, Sylvester R, van der Meijden, Oosterlinck W, Brausi M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol. 2000; 37( Suppl 3): 19.
  • 5
    Parmar MKB, Freedman LS, Hargreave TB, Tolley DA.. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party). J Urol. 1989; 142: 284288.
  • 6
    Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R, Members of the European Organization for Research and Treatment of Cancer Genitourinary Group. A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993; 149: 749752.
  • 7
    Tolley DA, Parmar MKB, Grigor KM, Lallemand G, Medical Research Council Superficial Bladder Cancer Working Party. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol 1996; 155: 12331238.
  • 8
    Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H. Rapid uptake by cultured tumor cells and intracellular behavior of 4′-O-tetrahydropyranyladriamycin. J Antibiot. 1983; 36: 312317.
  • 9
    Akaza H, Niijima T, Hisamatsu T, Fujigaki M. Comparative investigation on use of (2″R)-4′-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors. Urology. 1988; 32: 141145.
  • 10
    Yamamoto Y, Nasu Y, Saika T, Aaeda T, Tsushima T, Kumon H. The absorption of pirarubicin instilled intravesicaly immediately after transurethral resection of superficial bladder cancer. BJU Int. 2000; 86: 802804.
  • 11
    Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-Adriamycin (THP) for a single superficial bladder cancer: an interim report. J Urol. 1999; 161( Suppl): 171.
  • 12
    Ali-El-Dein B, Nabeeh A, El-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: prospective, randomized controlled study. Br J Urol. 1997; 79: 731735.
  • 13
    Rajala P, Liukkonen T, Raitanen M, et al. Transurethral resection with perioperative instillation of interferon-α or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J Urol. 1999; 161: 11331136.
  • 14
    Solsona E, Iborra I, Ricós JV, Monrós L, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol. 1999; 161: 11201123.
  • 15
    Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized double-blind, controlled trial. J Urol. 1983; 129: 505509.
  • 16
    Prout GR, Koontz WW, Coomms LJ, Hawkins IR, Friedell GH. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol. 1983; 130: 677680.